Potential of Antibiotics for the Treatment and Management of Parkinson's Disease: An Overview

(E-pub Ahead of Print)

Author(s): Narayan Yadav, Ajit Kumar Thakur*, Nikhila Shekhar, Ayushi

Journal Name: Current Drug Research Reviews
(Formerly Current Drug Abuse Reviews)


Become EABM
Become Reviewer
Call for Editor

Abstract:

Evidences have emerged over the last 2 decades to ascertain the proof of concepts viz. mitochondrial dysfunction, inflammation-derived oxidative damage and cytokine-induced toxicity that play a significant role in Parkinson's disease (PD). The available pharmacotherapies for PD are mainly symptomatic and typically indications of L-DOPA to restrain dopamine deficiency and their consequences. In the 21st century, the role of the antibiotics has emerged at the forefront of medicine in health and human illness. There are several experimental and pre-clinical evidences that supported the potential use of antibiotic as neuroprotective agent. The astonishing effects of antibiotics and their neuroprotective properties against neurodegeneration and neuro-inflammation would be phenomenal for the development of effective therapy against PD. Antibiotics are also testified as useful not only to prevent the formation of alpha-synuclein but also act on mitochondrial dysfunction and neuro-inflammation. Thus, the possible therapy with antibiotics in PD would impact both the pathways leading to neuronal cell death in substantia nigra and pars compacta in midbrain. Moreover, the antibiotic based pharmacotherapy will open a scientific research passageway to add more to the evidence based and rational use of antibiotics for the treatment and management of PD and other neurodegenerative disorders.

Keywords: Antibiotic, neuro-inflammation, neurodegeneration, oxidative damage, Parkinson disease, neuroprotection.

Rights & PermissionsPrintExport Cite as

Article Details

Published on: 14 March, 2021
(E-pub Ahead of Print)
DOI: 10.2174/2589977513666210315095133
Price: $95

Article Metrics

PDF: 134